Moreover, TTN mutations have been found to be associated with the objective response to immune checkpoint blockade (ICB) therapy (74).These findings highlight the potential impact of TP53 and TTN mutations in modulating the immune response within the tumor microenvironment and their relevance to clinical outcomes. This evidence concerns the gene TP53 and neoplasm.